Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHASIT sequential chemo-immunotherapy before radical surgery in locally advanced urothelial cancer
NL-OMON60898Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in transitional cell carcinoma (TCC), sponsored by Erasmus MC. Primary endpoint: Pathological complete response rate. Started Oct 2024; status: recruiting.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON60898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60898.